Last updated: August 11, 2026
ECOZA is a prescription topical antifungal containing econazole nitrate 1% in a foam formulation. The FDA approved ECOZA in 2013 for interdigital tinea pedis in patients aged 12 years and older. Its commercial opportunity is limited by the low medical severity of athlete's foot, extensive over-the-counter competition, established generic econazole products, and limited differentiation beyond the foam vehicle. [1]
Product-level revenue, profitability, prescription volume, and current market share for ECOZA are not publicly disclosed in FDA materials or a transparent public-company reporting series. The available evidence supports a niche branded-dermatology product rather than a high-growth or blockbuster asset.
What is ECOZA and which patients does it treat?
ECOZA contains econazole nitrate 1% and is applied once daily for four weeks to treat interdigital tinea pedis, commonly called athlete's foot. The product is a topical foam rather than a cream, solution, or aerosol spray. [1]
| Attribute |
ECOZA |
| Active ingredient |
Econazole nitrate |
| Strength |
1% |
| Dosage form |
Topical foam |
| FDA approval |
2013 |
| Approved indication |
Interdigital tinea pedis |
| Minimum labeled age |
12 years |
| Typical treatment duration |
Four weeks |
| Route |
Topical |
| Regulatory category |
Prescription drug |
The narrow indication affects market size. ECOZA is not broadly labeled for all superficial fungal infections, systemic fungal disease, or inflammatory dermatoses. Physicians can prescribe topical antifungals for other conditions, but those uses are outside the product's approved indication.
How large is the market for ECOZA?
The addressable market is the U.S. topical antifungal market, but ECOZA competes for only a fraction of total category demand.
The market has four principal segments:
- OTC products, including terbinafine, clotrimazole, miconazole, and butenafine.
- Generic prescription creams and solutions.
- Branded prescription formulations with differentiated vehicles.
- Dermatology products prescribed when patients have recurrent disease, treatment failure, adherence problems, or diagnostic uncertainty.
OTC products create the largest structural constraint. Consumers can purchase effective antifungal therapies without a physician visit, and many payers treat branded topical antifungals as nonpreferred products or exclude them from coverage.
ECOZA's foam formulation can support use in patients who dislike creams, have difficulty spreading semisolid products between the toes, or prefer a vehicle that dries quickly. That benefit is commercially relevant but usually insufficient to support broad premium pricing in a category with multiple low-cost alternatives.
What are ECOZA's main competitive threats?
OTC terbinafine and butenafine
Terbinafine and butenafine are strong commercial competitors because they have high consumer awareness, broad retail distribution, and established efficacy in tinea pedis. Their OTC availability reduces the number of patients who seek prescription treatment.
Generic econazole
Generic econazole nitrate cream and other topical econazole products compete directly on active ingredient and therapeutic class. A prescriber who wants econazole does not necessarily need the branded foam formulation.
Other prescription antifungals
Prescription competitors include generic ciclopirox, ketoconazole, naftifine, oxiconazole, sertaconazole, and topical azole products. The choice often depends on formulary status, patient history, diagnosis, physician preference, and pharmacy availability.
| Competitive factor |
ECOZA position |
| Active ingredient differentiation |
Low |
| Vehicle differentiation |
Moderate |
| OTC competitive pressure |
High |
| Generic substitution risk |
High |
| Prescriber familiarity |
Established for econazole, less differentiated for foam |
| Payer leverage |
Generally unfavorable for branded topical products |
| Switching cost |
Low |
| Treatment duration |
Four weeks, which is common for topical antifungal therapy |
What is ECOZA's FDA regulatory status?
ECOZA is an FDA-approved prescription product under New Drug Application 204153. The approved use is interdigital tinea pedis in patients aged 12 years and older. The FDA-approved labeling does not establish ECOZA as a treatment for broader dermatophyte infections or candidiasis. [1]
The product is not a biologic, so biosimilar competition is not relevant. Future competition would come through generic drug applications, branded topical antifungal products, or OTC alternatives.
The main regulatory risks are commercial rather than clinical. A generic applicant would need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA requirements for a topical semisolid or foam product. The complexity of a foam vehicle can raise development and manufacturing requirements compared with a conventional cream, but it does not eliminate generic-entry risk.
What patents and exclusivity protect ECOZA?
ECOZA's commercial protection is likely to depend more on formulation and manufacturing know-how than on the underlying econazole molecule. Econazole is an established antifungal active ingredient, so composition-of-matter protection for the active drug is not the basis of the product's value.
Potential protection categories include:
- Foam composition and excipient selection.
- Physical stability and container compatibility.
- Manufacturing process controls.
- Packaging and dispensing characteristics.
- Method-of-use claims tied to the approved indication.
- Regulatory exclusivity associated with the original NDA, where applicable.
FDA approval in 2013 does not by itself imply that market exclusivity remains active. The duration and practical value of any patent estate depend on issued claims, terminal disclaimers, patent-term adjustment, listed patents, and litigation outcomes. The relevant commercial question is whether a generic applicant can design around the foam formulation or challenge the remaining claims.
The Orange Book should be used to verify current patent listings and any applicable regulatory exclusivity. [2] A current, product-specific public revenue analysis should not treat historical patent issuance as proof of continuing market exclusivity.
When did ECOZA lose exclusivity?
ECOZA's small-molecule regulatory exclusivity, if applicable, would have expired years before the present market period. The principal remaining barrier, if any, would be patent protection or the technical difficulty of developing an equivalent foam.
The four-year Hatch-Waxman data-exclusivity period for a new chemical entity would not ordinarily explain current commercial protection for a product approved in 2013. The more relevant generic-entry variables are:
- Whether ECOZA has current Orange Book-listed patents.
- Whether those patents claim the product broadly or only specific formulation features.
- Whether an ANDA applicant can obtain approval without infringing valid claims.
- Whether the product's commercial sales justify generic-development costs.
For a low-volume topical product, a generic company may defer development even after legal barriers weaken if the expected market is too small or physician substitution is limited.
How strong is ECOZA's patent estate?
ECOZA's patent strength should be viewed as moderate at most unless the owner controls broad, difficult-to-design-around foam claims. The underlying active ingredient provides little defensibility because econazole is old and widely available.
A stronger estate would require claims covering:
- The specific foam architecture.
- A necessary combination of solvents, propellants, surfactants, and stabilizers.
- Performance characteristics that are difficult to reproduce.
- Manufacturing parameters required to achieve the labeled product.
- A meaningful method-of-use limitation with commercial relevance.
A weaker estate would consist mainly of narrow formulation claims that can be avoided through a different excipient system or dosage form. In topical pharmaceuticals, formulation patents can delay competition, but they often support only limited exclusivity compared with composition-of-matter patents.
What is ECOZA's financial trajectory?
There is no reliable public product-level revenue series for ECOZA. Neither the FDA approval record nor standard public labeling provides sales, prescription volume, net price, gross margin, or operating-profit data. Any precise revenue estimate would require proprietary prescription, claims, or wholesaler data.
The likely financial profile has four characteristics:
Low absolute revenue ceiling
ECOZA treats a common, generally self-managed infection. The product does not address a high-cost specialty disease, chronic systemic condition, or large hospital market. Its revenue ceiling is therefore constrained even if the brand maintains a premium price.
High gross-to-net exposure
Branded topical products commonly face payer restrictions, coupon use, pharmacy benefit-manager rebates, and patient abandonment. A high list price does not necessarily translate into high realized revenue.
Limited research and development burden
ECOZA is an approved topical product with a mature active ingredient. Ongoing expenditure is more likely to involve manufacturing, quality, regulatory maintenance, sales promotion, and lifecycle management than clinical development.
Low fixed-cost scalability
A niche topical product can generate attractive contribution margins if manufacturing is efficient and commercial spending is controlled. The opposite is also possible: a small prescription base can make sales-force and promotional costs disproportionate to revenue.
The most defensible financial conclusion is that ECOZA is a mature, niche commercial asset with uncertain but likely modest annual sales and limited growth without a new indication, improved reimbursement, expanded distribution, or a transaction that places it in a larger dermatology portfolio.
Which companies are challenging ECOZA?
No publicly established Paragraph IV litigation or settlement involving an ECOZA generic should be assumed without a current court-docket and FDA Orange Book review. A Paragraph IV challenge would require an ANDA applicant to certify that relevant listed patents are invalid, unenforceable, or not infringed.
Generic challengers would likely evaluate:
- Market size relative to development cost.
- Complexity of reproducing the foam.
- Availability of alternative econazole formulations.
- Remaining patent term.
- Expected price erosion after launch.
- Whether the branded product has meaningful formulary access.
For a modest-volume topical product, the absence of visible litigation does not necessarily indicate strong patent protection. It can also reflect limited generic economics.
What generic launch scenarios exist for ECOZA?
Scenario 1: No near-term generic launch
The branded product remains available, but generic manufacturers do not pursue the formulation because the opportunity is too small or technically unattractive. Revenue declines gradually as prescribers use cheaper alternatives.
Scenario 2: One authorized or authorized-equivalent competitor
A single competitor enters with limited price erosion. The brand retains some prescriptions through physician familiarity, coupons, or payer positioning.
Scenario 3: Multiple generic foam products
Several entrants create rapid price erosion and pharmacy substitution. The brand may retain a narrow cash-pay or specialty-prescriber segment.
Scenario 4: Cream substitution without a foam generic
Generic econazole cream and other topical antifungals continue to capture prescriptions even without a directly equivalent foam. This scenario reduces ECOZA demand through therapeutic substitution rather than formal generic substitution.
The fourth scenario is commercially important. ECOZA does not need a therapeutically equivalent foam generic to lose share.
What manufacturing and intellectual-property barriers affect ECOZA?
Foam products can require tighter control of viscosity, propellant behavior, emulsion stability, package compatibility, and dose delivery. These factors can increase formulation-development and scale-up costs. They may also create quality-control risks if the product is stored under varying temperature conditions.
The barriers are meaningful but not necessarily durable. A technically competent generic manufacturer can often develop an alternative formulation or pursue a product that satisfies FDA requirements without duplicating every aspect of the branded composition.
Manufacturing economics also matter. Low-volume production can result in higher unit costs, contract-manufacturing dependence, and inventory risk. The commercial owner must balance minimum production runs against uncertain demand.
How does ECOZA compare with generic econazole cream?
| Metric |
ECOZA foam |
Generic econazole cream |
| Active ingredient |
Econazole nitrate |
Econazole nitrate |
| Formulation |
Foam |
Cream |
| Brand status |
Branded prescription product |
Generic prescription product |
| Convenience differentiation |
Higher for some patients |
Familiar, widely available |
| Expected price |
Usually higher |
Lower |
| Payer position |
More vulnerable |
Generally stronger |
| Generic substitution |
Direct risk if foam equivalent launches |
Already established |
| Commercial moat |
Vehicle and possible formulation IP |
Low cost and availability |
ECOZA's value proposition depends on delivery system convenience, not on a new antifungal mechanism. That limits pricing power and makes market access central to performance.
What licensing and transaction activity affects ECOZA?
Public disclosures do not establish a current, product-specific licensing deal that can be used to forecast ECOZA revenue. The FDA labeling identifies Quinnova Pharmaceuticals as the product company associated with the approved label. [1]
A future licensing or acquisition transaction would likely be assessed on:
- Net sales rather than list price.
- Prescription retention and refill rates.
- Payer coverage.
- Remaining patent term.
- Manufacturing margin.
- Sales-force overlap with other dermatology products.
- Geographic rights.
- Liability for quality, recalls, and regulatory compliance.
ECOZA is more likely to create value as part of a dermatology portfolio than as a standalone growth platform. Portfolio owners can share sales infrastructure and use existing payer relationships, reducing the product's standalone commercial burden.
What geographic markets does ECOZA cover?
The principal documented regulatory market is the United States. U.S. approval does not establish approval, pricing, reimbursement, or commercial availability in Europe, Canada, Japan, or other jurisdictions.
International expansion would require local regulatory filings, country-specific labeling, pricing negotiations, distribution arrangements, and potentially different patent positions. Given the common indication and intense OTC competition, international expansion would require a clear commercial partner or a differentiated reimbursement strategy.
Key Takeaways
- ECOZA is a prescription econazole nitrate 1% foam approved in 2013 for interdigital tinea pedis.
- Its commercial differentiation comes from the foam vehicle, not from a novel active ingredient.
- OTC terbinafine, butenafine, clotrimazole, and miconazole create substantial market pressure.
- Generic econazole and other prescription antifungals limit pricing power.
- Product-level ECOZA revenue, profit, market share, and prescription data are not publicly disclosed.
- The asset is best characterized as a mature niche dermatology product with modest revenue potential.
- Patent value depends on the breadth and remaining term of formulation and manufacturing claims.
- Biosimilar risk is irrelevant because ECOZA is a small-molecule topical drug.
- Generic entry could occur through a direct foam equivalent or through therapeutic substitution with lower-cost creams.
- Portfolio ownership and shared commercial infrastructure are more likely to improve economics than major organic market expansion.
FAQs
Is ECOZA available over the counter?
No. ECOZA is an FDA-approved prescription topical antifungal. OTC econazole is not the principal U.S. substitute, but several other topical antifungals are sold without a prescription. [1]
Is ECOZA stronger than terbinafine?
The products contain different active ingredients and should not be ranked solely by strength. Terbinafine is a major competitor for tinea pedis and is widely available OTC. Treatment selection depends on diagnosis, patient history, formulation preference, and clinician judgment.
Can pharmacies automatically substitute generic econazole cream for ECOZA foam?
Automatic substitution depends on state law, pharmacy-benefit rules, and whether the products are considered therapeutically equivalent for substitution purposes. A cream and foam are different dosage forms, so therapeutic substitution may require prescriber or payer involvement.
Does ECOZA have biosimilar competition?
No. Biosimilars apply to biologic products. ECOZA is a small-molecule topical drug and would face generic-drug, branded-drug, and OTC competition instead.
Is ECOZA likely to become a blockbuster drug?
No. The indication is common but generally low severity, the active ingredient is mature, and the market has extensive OTC and generic competition. Without a significant indication expansion or major distribution change, ECOZA's economics are more consistent with a niche branded dermatology product.
References
-
U.S. Food and Drug Administration. (2013). Ecoza (econazole nitrate) foam, 1%: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204153s000lbl.pdf
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
